EA202190669A1 - Процесс получения вакцинной композиции - Google Patents

Процесс получения вакцинной композиции

Info

Publication number
EA202190669A1
EA202190669A1 EA202190669A EA202190669A EA202190669A1 EA 202190669 A1 EA202190669 A1 EA 202190669A1 EA 202190669 A EA202190669 A EA 202190669A EA 202190669 A EA202190669 A EA 202190669A EA 202190669 A1 EA202190669 A1 EA 202190669A1
Authority
EA
Eurasian Patent Office
Prior art keywords
stimulating
cancer
treatment
pharmaceutical compositions
compositions containing
Prior art date
Application number
EA202190669A
Other languages
English (en)
Inventor
Юлианна Лисёиц
Левенте Мольнар
Энико Токе
Йожеф ТОТ
Оршойа Лоринц
Жольт Чисовски
Эстер Шомодьи
Каталин Пантья
Моника Медьеши
Петер Палеш
Original Assignee
Треош Био Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Треош Био Лимитед filed Critical Треош Био Лимитед
Publication of EA202190669A1 publication Critical patent/EA202190669A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Abstract

Настоящее изобретение относится к полипептидам, полинуклеиновым кислотам и фармацевтическим композициям, содержащим полипептиды, которые находят применение в профилактике или лечении рака. Изобретение также относится к способам стимулирования цитотоксического Т-клеточного ответа у субъекта или к лечению рака путем введения фармацевтических композиций, содержащих пептиды, и к сопутствующим диагностическим способам. Изобретение также относится к способу получения пептида или полинуклеиновой кислоты для использования в способе стимулирования Т-клеточного ответа против целевого полипептида, причем способ включает в себя идентификацию эпитопов в антигене, которые связываются с множеством аллелей HLA у наибольшей доли субъектов в целевой популяции.
EA202190669A 2018-09-04 2019-09-03 Процесс получения вакцинной композиции EA202190669A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1814362.8A GB201814362D0 (en) 2018-09-04 2018-09-04 Composition and process for preparing vaccine
PCT/EP2019/073481 WO2020048995A1 (en) 2018-09-04 2019-09-03 Process for preparing vaccine compositions

Publications (1)

Publication Number Publication Date
EA202190669A1 true EA202190669A1 (ru) 2021-06-03

Family

ID=63920945

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202190669A EA202190669A1 (ru) 2018-09-04 2019-09-03 Процесс получения вакцинной композиции

Country Status (17)

Country Link
US (3) US20200069786A1 (ru)
EP (1) EP3847185A1 (ru)
JP (1) JP2021535749A (ru)
KR (1) KR20210086610A (ru)
CN (1) CN113383009A (ru)
AU (1) AU2019334261A1 (ru)
BR (1) BR112021004075A2 (ru)
CA (1) CA3110923A1 (ru)
CL (1) CL2021000534A1 (ru)
CO (1) CO2021004028A2 (ru)
EA (1) EA202190669A1 (ru)
GB (1) GB201814362D0 (ru)
IL (1) IL281220A (ru)
MA (1) MA53544A (ru)
MX (1) MX2021002543A (ru)
SG (1) SG11202101881UA (ru)
WO (1) WO2020048995A1 (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180264095A1 (en) 2017-03-03 2018-09-20 Treos Bio Zrt Population-based immunogenic peptide identification platform
GB201804468D0 (en) * 2018-03-21 2018-05-02 Valo Therapeutics Oy PeptiCRAd Cancer Therapy
MA53543A (fr) 2018-09-04 2021-07-14 Treos Bio Ltd Vaccins peptidiques
GB202004974D0 (en) 2020-04-03 2020-05-20 Treos Bio Ltd Coronavirus vaccine
US20230190902A1 (en) * 2020-05-29 2023-06-22 Children's National Medical Center Identification of hla-restricted prame peptide epitopes, prame-specific t cells suitable for "off-the-shelf" treatment of cancer expressing prame
CN111617238B (zh) * 2020-06-02 2022-12-13 苏州药明康德新药开发有限公司 小鼠ct26结直肠癌治疗性肿瘤多肽疫苗制剂及其制备方法
EP3945320A1 (en) * 2020-07-29 2022-02-02 Corporació Sanitària Parc Taulí Improved epitope for detecting and/or quantifying autoantibodies against alpha-fetoprotein
EP4236981A1 (en) * 2020-10-28 2023-09-06 Follicum AB Peptides for use in skin and hair pigmentation
CN113144181B (zh) * 2021-04-20 2022-07-19 徐州医科大学 一种靶向b7h3的dna疫苗、制备方法及应用
CN114195861A (zh) * 2022-01-05 2022-03-18 许昌学院 亲和肽
CN115785211A (zh) * 2022-06-10 2023-03-14 河北博海生物工程开发有限公司 肺癌特异性分子靶标04及其用途
CN115785204B (zh) * 2022-06-10 2024-02-13 河北博海生物工程开发有限公司 肺癌特异性分子靶标08及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
FR2791895B1 (fr) 1999-03-23 2001-06-15 Pasteur Merieux Serums Vacc Utilisation de trehalose pour stabiliser un vaccin liquide
AUPQ776100A0 (en) * 2000-05-26 2000-06-15 Australian National University, The Synthetic molecules and uses therefor
GB0520067D0 (en) * 2005-10-01 2005-11-09 Cancer Rec Tech Ltd Treatment of cancer
GB201315946D0 (en) * 2013-09-06 2013-10-23 Immune Targeting Systems Its Ltd Oncology vaccine
EP3369431A1 (en) 2017-03-03 2018-09-05 Treos Bio Kft Vaccine
EP3370065A1 (en) 2017-03-03 2018-09-05 Treos Bio Kft Immunogenic peptides
US20180264095A1 (en) 2017-03-03 2018-09-20 Treos Bio Zrt Population-based immunogenic peptide identification platform

Also Published As

Publication number Publication date
WO2020048995A1 (en) 2020-03-12
CL2021000534A1 (es) 2021-09-24
MX2021002543A (es) 2021-08-11
AU2019334261A1 (en) 2021-03-18
MA53544A (fr) 2021-07-14
IL281220A (en) 2021-04-29
CA3110923A1 (en) 2020-03-12
JP2021535749A (ja) 2021-12-23
US20210236611A1 (en) 2021-08-05
US20200069786A1 (en) 2020-03-05
GB201814362D0 (en) 2018-10-17
CN113383009A (zh) 2021-09-10
EP3847185A1 (en) 2021-07-14
US20220160854A1 (en) 2022-05-26
BR112021004075A2 (pt) 2021-05-25
CO2021004028A2 (es) 2021-06-21
KR20210086610A (ko) 2021-07-08
SG11202101881UA (en) 2021-03-30

Similar Documents

Publication Publication Date Title
EA202190669A1 (ru) Процесс получения вакцинной композиции
EA202191027A2 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии нескольких видов опухолей
CN107624118A (zh) 用于肺癌(包括非小细胞肺癌和其他癌症)免疫治疗的新型肽和肽组合物
EA201791150A1 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии гепатоклеточной карциномы (гкк) и других видов рака
AU2022268324B2 (en) Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
AU2021282532B2 (en) Novel peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers
EA202190670A1 (ru) Пептидные вакцины
EA202190555A1 (ru) Рестриктированные по в*44 пептиды для применения в иммунотерапии раковых заболеваний и связанные с ними способы
EA202190169A1 (ru) Иммунотерапия раковых заболеваний рестриктированными по b*07 пептидами и комбинациями пептидов и относящиеся к ней способы
EA202190572A1 (ru) Иммунотерапия раковых заболеваний рестриктированными по a*01 пептидами и комбинациями пептидов и относящиеся к ней способы
EA201992417A1 (ru) Пептиды и их комбинации для применения в иммунотерапии раковых заболеваний
NZ791720A (en) Novel peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers
EA201992059A1 (ru) Платформа для идентификации иммуногенных пептидов популяционного уровня
EA201992860A1 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл), мелкоклеточного рака легких (мрл) и других видов рака
EA202092502A3 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии нескольких видов рака
EA202191013A3 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии и способы получения каркасов для применения при лечении рака поджелудочной железы и других видов рака